Literature DB >> 24449331

Best targeted sarcoma treatment: advances from the Musculoskeletal Tumor Society annual meeting.

John H Healey1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24449331      PMCID： PMC3916630          DOI： 10.1007/s11999-013-3455-z

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  4 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  First FDA authorization for next-generation sequencer.

Authors:  Francis S Collins; Margaret A Hamburg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

3.  ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.

Authors:  Lori Rink; Michael F Ochs; Yan Zhou; Margaret von Mehren; Andrew K Godwin
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

4.  Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.

Authors:  R J Motzer; B Escudier; R Bukowski; B I Rini; T E Hutson; C H Barrios; X Lin; K Fly; E Matczak; M E Gore
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.